EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR ‐ SCREEN ‐2 Study

Tadayoshi Hashimoto iD, Naoko Iida, Yoshiaki Nakamura iD, Norio Nonomura iD, Chigusa Morizane, Hiroji Iwata iD, Susumu Okano iD, Wataru Yamagami, Naoya Yamazaki iD, Shigenori Kadowaki, Makoto Ueno, Shogen Boku iD und 17 weitere

Cancer Science · 2025-08 · 116 (8) · 2218-2231

DOI: 10.1111/cas.70100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 02.06.2025. Verfasst von Tadayoshi Hashimoto und 28 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Claudins, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, SCRUM-Japan Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is well‐characterized in gastric cancer, but its pan‐cancer expression profiles and isoform distributions are poorly documented. In the present study, we analyzed CLDN18 expression in patients with solid tumors enrolled in the MONSTAR‐SCREEN‐2 study using immunohistochemistry (IHC, n = 349) and whole‐transcriptome sequencing (WTS, n = 2191). A splice junction analysis algorithm characterized isoform distribution patterns in WTS data and evaluated temporal changes using paired pre‐ and postchemotherapy specimens. IHC detected CLDN18.2 (≥ 40% of tumor cells showing any staining intensity) in 16.3% of patients, with highest prevalence in gastric (54.5%), biliary tract (21.7%), pancreatic (20.7%), and small intestinal (18.2%) cancers. WTS and IHC findings were significantly correlated ( p < 0.001). WTS analysis with optimized transcript thresholds ( n = 2191) demonstrated the CLDN18 ‐high population to be 13.8%, with highest proportions in gastric (64.5%), small intestinal (40.0%), pancreatic (37.8%), and biliary tract (20.0%) cancers. Isoform analysis of 364 patients revealed CLDN18.2 predominance (mean 18.2/18.1 proportion 0.945), with CLDN18.1 predominance observed in only 4.9% of patients. Longitudinal analysis of 27 paired gastric cancer samples revealed a significant reduction in CLDN18 expression and a nonsignificant decrease in the CLDN18.2 proportion following chemotherapy. This analysis validates WTS as a complementary approach to IHC for CLDN18 assessment and demonstrates significant CLDN18 expression across multiple cancer types. The predominance of CLDN18.2 supports the expansion of targeted therapeutic approaches beyond gastric cancer and indicates the potential of RNA‐based screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClaudinsNeoplasmsHumansProtein IsoformsMaleFemaleMiddle AgedAgedImmunohistochemistryGene Expression Regulation, NeoplasticGene Expression ProfilingBiomarkers, TumorStomach NeoplasmsTranscriptomeAdult

Stichwörter der Autor:innen

claudin18immunohistochemistryisoformpan‐cancerwhole‐transcriptome sequencing

Substanzen

ClaudinsCLDN18 protein, humanProtein IsoformsBiomarkers, Tumor

Autor:innen und Institutionen

  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Advanced Clinical Research and Development, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

ORCID-Profile: Tadayoshi Hashimoto, Yoshiaki Nakamura, Norio Nonomura, Hiroji Iwata, Susumu Okano, Naoya Yamazaki, Shogen Boku, Eiji Oki, Satoshi Yuki, Naohiro Okano, Naoya Sakamoto, Hideaki Bando, Kohei Shitara, Takayuki Yoshino

Förderung

  • Japan Agency for Medical Research and Development
  • SCRUM-Japan Funds

Zitieren

APA

Hashimoto, T., Iida, N., Nakamura, Y., Nonomura, N., Morizane, C., Iwata, H., Okano, S., Yamagami, W., Yamazaki, N., Kadowaki, S., Ueno, M., Boku, S., Oki, E., Komatsu, Y., Yuki, S., Makiyama, A., Ogata, T., Takahashi, N., Okano, N., …, & Yoshino, T. (2025). Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR ‐ SCREEN ‐2 Study. Cancer Science, 116(8), 2218-2231. https://doi.org/10.1111/cas.70100

Vancouver

Hashimoto T, Iida N, Nakamura Y, Nonomura N, Morizane C, Iwata H, et al. Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR ‐ SCREEN ‐2 Study. Cancer Science. 2025;116(8):2218-2231. doi:10.1111/cas.70100

BibTeX
@article{Hashimoto2025,
  author = {Hashimoto, Tadayoshi and Iida, Naoko and Nakamura, Yoshiaki and Nonomura, Norio and Morizane, Chigusa and Iwata, Hiroji and Okano, Susumu and Yamagami, Wataru and Yamazaki, Naoya and Kadowaki, Shigenori and Ueno, Makoto and Boku, Shogen and Oki, Eiji and Komatsu, Yoshito and Yuki, Satoshi and Makiyama, Akitaka and Ogata, Takatsugu and Takahashi, Naoki and Okano, Naohiro and Nishina, Tomohiro and Sakamoto, Naoya and Kuwata, Takeshi and Yamashita, Riu and Shibuki, Taro and Imai, Mitsuho and Fujisawa, Takao and Bando, Hideaki and Shitara, Kohei and Yoshino, Takayuki},
  title = {Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR ‐ SCREEN ‐2 Study},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {8},
  pages = {2218--2231},
  doi = {10.1111/cas.70100}
}
Kostenlos starten →